A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer
Status:
Not yet recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
This study is being done to evaluate the safety and efficacy of adding NIS793 to standard of
care FOLFIRINOX treatment for pancreatic cancer.
The names of the study interventions involved in this study are:
- NIS793
- FOLFIRINOX (Folinic acid/Leucovorin, 5-Fluorouracil, Irinotecan, and Oxaliplatin)
Other interventions may include:
- Chemoradiation Therapy
- Surgery